NCT05860478

Brief Summary

This protocol is for a pragmatic mixed methods randomized parallel-group exploratory feasibility trial to examine all facets of a proposed future phase III trial on the use of wearable device to increase physical activity and possibly reduce pain amongst middle-aged people with musculoskeletal (MSK) chronic pain. The feasibility study is intended to answer the following research questions: Question 1 Evaluate the acceptability of all aspect of the study design of wearable devices as an intervention to increase physical activity in middle-aged adults with musculoskeletal chronic pain. Question 2: Is it feasible and acceptable to use wearable devices as an intervention to increase physical activity in middle-aged adults with musculoskeletal chronic pain? Question 3: How can using wearable device promote physical activity effectively in middle-aged adults with musculoskeletal chronic pain? Participants will be recruited from a National Health Service (NHS) pain clinic and randomised on a ratio1:3 into control group (standard care) and intervention group (standard care combined with wearable device). The feasibility study will last for 18 months, participants involvement will be for 24 weeks. Patients in both groups can participate in any physical activity, including planned, structured, and repetitive bodily movement exercise or occupational and recreational PA. Qualitative semi-structured interview will be conducted at baseline and week-12, while outcome measures will be conducted at baseline, 4-week, 8-week,12-week, and 24-week for all participants to examine their pain, physical activity, and their responses to the trial. Qualitative interview will be conducted for stakeholders which include clinicians and service managers after all patient data has been collected. This study has the potential to make an original contribution to provide key data on the feasibility, acceptability, and effectiveness of using wearable technology to support physical activity intervention for middle-aged adults with musculoskeletal chromic pain.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Oct 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 7, 2023

Completed
1 month until next milestone

First Posted

Study publicly available on registry

May 16, 2023

Completed
5 months until next milestone

Study Start

First participant enrolled

October 6, 2023

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2024

Completed
Last Updated

April 29, 2024

Status Verified

April 1, 2024

Enrollment Period

6 months

First QC Date

April 7, 2023

Last Update Submit

April 26, 2024

Conditions

Outcome Measures

Primary Outcomes (9)

  • Change in Brief Pain Inventory

    Participants in both groups will complete outcome measures at baseline (T0), week 4 (T1), week 8 (T2), week 12 (T3), and week 24 (T4)

  • Change in Visual Analogue Scale (VAS) of Quality of Life

    Participants in both groups will complete outcome measures at baseline (T0), week 4 (T1), week 8 (T2), week 12 (T3), and week 24 (T4)

  • Change in Visual Analogue Scale (VAS) of pain

    Participants in both groups will complete outcome measures at baseline (T0), week 4 (T1), week 8 (T2), week 12 (T3), and week 24 (T4)

  • Change in Numerical Pain Rating Scale (NPRS)

    Participants in both groups will complete outcome measures at baseline (T0), week 4 (T1), week 8 (T2), week 12 (T3), and week 24 (T4)

  • Change in EuroQol Five-Dimensional Questionnaire (EQ-5D-5L)

    Participants in both groups will complete outcome measures at baseline (T0), week 4 (T1), week 8 (T2), week 12 (T3), and week 24 (T4)

  • Change in Pain Catastrophising Scale

    Participants in both groups will complete outcome measures at baseline (T0), week 4 (T1), week 8 (T2), week 12 (T3), and week 24 (T4)

  • Change in The International Physical Activity Questionnaire (IPAQ)

    Participants in both groups will complete outcome measures at baseline (T0), week 4 (T1), week 8 (T2), week 12 (T3), and week 24 (T4)

  • Change in Chronic Pain Coping Inventory (CPCI)

    Participants in both groups will complete outcome measures at baseline (T0), week 4 (T1), week 8 (T2), week 12 (T3), and week 24 (T4)

  • Change in Warwick-Edinburgh Mental Well-Being Scale (WEMWBS)

    Participants in both groups will complete outcome measures at baseline (T0), week 4 (T1), week 8 (T2), week 12 (T3), and week 24 (T4)

Study Arms (2)

wearable device plus standard care

EXPERIMENTAL
Device: Wearable device

standard care

NO INTERVENTION

Interventions

The wearable device includes a motion sensor, and is worn around the wrist, and the device records a participant's physical activity .

wearable device plus standard care

Eligibility Criteria

Age40 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient of any gender identity 40-65 years old.
  • Willingness to participate in the trial.
  • Able to understand and speak sufficient English to engage during interviews.
  • They have self-reported persistent or recurrent musculoskeletal pain for three months or longer.
  • Participants will be receiving treatment for musculoskeletal chronic pain.

You may not qualify if:

  • Palliative patient.
  • Patients of any gender identity younger than 40-year-old or older than 65-year-old.
  • Patients that are dependent on alcohol or drugs.
  • Involvement with other ongoing studies.
  • Patients unable to complete the questionnaires as judged by the researcher.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Royal London Hospital for Integrated Medicine, UCLH NHS Foundation Trust

London, WC1N 3HR, United Kingdom

RECRUITING

MeSH Terms

Interventions

Wearable Electronic Devices

Intervention Hierarchy (Ancestors)

Electrical Equipment and SuppliesEquipment and Supplies

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

April 7, 2023

First Posted

May 16, 2023

Study Start

October 6, 2023

Primary Completion

April 1, 2024

Study Completion

April 1, 2024

Last Updated

April 29, 2024

Record last verified: 2024-04

Locations